# Sales of Entresto sank 42% to $1.31 billion after its U.S. patents expired last year.

*biotech · news · 2026-04-28 · Devdiscourse*

## Key points

- Novartis' Entresto sales fell 42% to $1.31 billion, below analyst expectations of $1.37 billion.
- Novartis expects a $4 billion sales decline this year due to Entresto's U.S. generic competition.
- Patent expiries for Cosentyx, Kesimpta, and Kisqali are set for early 2030s, increasing future risk.
- Novartis is relying on Kisqali and Kesimpta growth to offset declining Entresto revenues.

**Companies:** Novartis
**Countries:** Switzerland, United States, Germany, Japan

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/technology/3889464-update-4-novartis-posts-earnings-miss-as-generic-rivals-hurt-blockbuster-drug-entresto)

---

Canonical: https://newsio.io/n/1403039d-2754-4f9e-9d7f-c5454e30e6eb/sales-of-entresto-sank-42-to-1-31-billion-after-its-u-s-patents-expired-last-yea
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works